Ningbo Menovo Pharmaceutical Co., Ltd.
Символ: 603538.SS
SHH
13.22
CNYПазарна цена днес
15.0564
Съотношение P/E
2.4090
Коефициент PEG
2.79B
MRK Cap
- 0.01%
Доходност на DIV
Ningbo Menovo Pharmaceutical Co., Ltd. (603538-SS) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3762.73 | 1009.3 | 793.2 | 368.8 | ||||||||||||
balance-sheet.row.short-term-investments | 953.75 | 217.4 | 371.4 | 133.1 | ||||||||||||
balance-sheet.row.net-receivables | 1047.59 | 231.5 | 266.2 | 193.4 | ||||||||||||
balance-sheet.row.inventory | 2600.3 | 594.4 | 579.7 | 454.7 | ||||||||||||
balance-sheet.row.other-current-assets | 215.51 | 59.2 | 63.4 | 117.3 | ||||||||||||
balance-sheet.row.total-current-assets | 7626.13 | 1894.4 | 1702.4 | 1134.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 7446.1 | 1801.9 | 1614.7 | 1145 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 22.7 | 22.7 | ||||||||||||
balance-sheet.row.intangible-assets | 727.46 | 172.5 | 201.7 | 224.7 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 727.46 | 172.5 | 224.4 | 247.4 | ||||||||||||
balance-sheet.row.long-term-investments | 275.64 | 82.7 | -51.8 | 275.4 | ||||||||||||
balance-sheet.row.tax-assets | 490.14 | 123.1 | 33.3 | 45.5 | ||||||||||||
balance-sheet.row.other-non-current-assets | 1264.07 | 344.8 | 478.5 | 215.3 | ||||||||||||
balance-sheet.row.total-non-current-assets | 10203.4 | 2525.1 | 2299.1 | 1928.6 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 17829.53 | 4419.5 | 4001.5 | 3062.7 | ||||||||||||
balance-sheet.row.account-payables | 1977.89 | 499.3 | 389.1 | 373 | ||||||||||||
balance-sheet.row.short-term-debt | 2115.99 | 497 | 505 | 648.9 | ||||||||||||
balance-sheet.row.tax-payables | 222.92 | 72.1 | 34.6 | 7.6 | ||||||||||||
balance-sheet.row.long-term-debt-total | 2914.97 | 705.6 | 755.3 | 108.5 | ||||||||||||
Deferred Revenue Non Current | 309.7 | 70.6 | 48.7 | 24.2 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 397.52 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 341.01 | 171 | 3.9 | 2.1 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 3641.57 | 884 | 876.2 | 187.9 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 129.1 | 30.3 | 28 | 26.8 | ||||||||||||
balance-sheet.row.total-liab | 9021.27 | 2246.2 | 2023 | 1300.2 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 853.59 | 213.4 | 151.3 | 149.6 | ||||||||||||
balance-sheet.row.retained-earnings | 4995.7 | 1234.3 | 937.4 | 811.8 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1644.68 | 101.4 | 77.6 | 33.6 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 948.88 | 535.9 | 585.2 | 556.7 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 8442.85 | 2085 | 1751.5 | 1551.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 17829.53 | 4419.5 | 4001.5 | 3062.7 | ||||||||||||
balance-sheet.row.minority-interest | 365.41 | 88.3 | 227 | 210.8 | ||||||||||||
balance-sheet.row.total-equity | 8808.26 | 2173.2 | 1978.5 | 1762.5 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 17829.53 | - | - | - | ||||||||||||
Total Investments | 1229.39 | 300.1 | 319.6 | 408.6 | ||||||||||||
balance-sheet.row.total-debt | 5030.96 | 1202.6 | 1260.4 | 757.4 | ||||||||||||
balance-sheet.row.net-debt | 2221.99 | 410.7 | 838.6 | 521.7 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 179.28 | 367.6 | 158.1 | 173.1 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 29 | 101.8 | 98.9 | 85 | ||||||||||||
cash-flows.row.deferred-income-tax | -53.87 | -40.2 | -21 | 18.4 | ||||||||||||
cash-flows.row.stock-based-compensation | 35.96 | 24.7 | 5.3 | 10.9 | ||||||||||||
cash-flows.row.change-in-working-capital | -396.61 | -85.4 | -62.2 | -2.8 | ||||||||||||
cash-flows.row.account-receivables | -213.63 | -213.6 | -50.9 | -28.2 | ||||||||||||
cash-flows.row.inventory | -182.99 | -183 | -124.7 | -83 | ||||||||||||
cash-flows.row.account-payables | -25.08 | 351.4 | 134.4 | 63.3 | ||||||||||||
cash-flows.row.other-working-capital | 25.08 | -40.2 | -21 | 45.1 | ||||||||||||
cash-flows.row.other-non-cash-items | 286.6 | -91.4 | 41.5 | -32.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 69.09 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -431.88 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.acquisitions-net | 454.01 | 487.9 | -47.1 | 0.5 | ||||||||||||
cash-flows.row.purchases-of-investments | -976.29 | -713.9 | -1640.5 | -865 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 1076.97 | 902.5 | 1562.2 | 693.5 | ||||||||||||
cash-flows.row.other-investing-activites | 31.77 | -54.6 | 52 | 3.8 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 154.59 | 50.3 | -603.3 | -479 | ||||||||||||
cash-flows.row.debt-repayment | -705.72 | -749.5 | -788.1 | -802.5 | ||||||||||||
cash-flows.row.common-stock-issued | 0.1 | 0.1 | 0.2 | 0.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | -0.1 | -0.1 | -0.2 | -0.5 | ||||||||||||
cash-flows.row.dividends-paid | -65.55 | -50 | -13.8 | -41 | ||||||||||||
cash-flows.row.other-financing-activites | 652.62 | 621.1 | 1385.1 | 981.9 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -118.66 | -178.5 | 583.1 | 138.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 18.18 | 14.6 | -2.3 | -2 | ||||||||||||
cash-flows.row.net-change-in-cash | -49.46 | 163.4 | 198.2 | -91 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 1735.4 | 537 | 373.6 | 174.5 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1784.86 | 373.6 | 175.4 | 265.5 | ||||||||||||
cash-flows.row.operating-cash-flow | 69.09 | 277 | 220.6 | 251.6 | ||||||||||||
cash-flows.row.capital-expenditure | -431.88 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.free-cash-flow | -362.79 | -294.7 | -309.3 | -60.1 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1154.83 | 1457 | 1258.1 | 1193.7 | ||||||||||||
income-statement-row.row.cost-of-revenue | 771.83 | 872.8 | 788.9 | 758.6 | ||||||||||||
income-statement-row.row.gross-profit | 383 | 584.2 | 469.2 | 435.1 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 91.47 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 61.81 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 58.15 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 117.43 | 116.4 | 110.8 | 109.9 | ||||||||||||
income-statement-row.row.operating-expenses | 324.09 | 341.4 | 281 | 236 | ||||||||||||
income-statement-row.row.cost-and-expenses | 1095.92 | 1214.2 | 1069.9 | 994.5 | ||||||||||||
income-statement-row.row.interest-income | 2.38 | 5.7 | 2.2 | 3 | ||||||||||||
income-statement-row.row.interest-expense | 28.52 | 27.4 | 27.2 | 26.2 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 58.15 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | -16.29 | -21.2 | -7.6 | -0.9 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 117.43 | 116.4 | 110.8 | 109.9 | ||||||||||||
income-statement-row.row.total-operating-expenses | -16.29 | -21.2 | -7.6 | -0.9 | ||||||||||||
income-statement-row.row.interest-expense | 28.52 | 27.4 | 27.2 | 26.2 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 55.21 | 128.3 | 124.1 | 152.3 | ||||||||||||
income-statement-row.row.ebitda-caps | 243.79 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 188.58 | 405.3 | 187.9 | 215.5 | ||||||||||||
income-statement-row.row.income-before-tax | 172.29 | 384.2 | 180.3 | 214.7 | ||||||||||||
income-statement-row.row.income-tax-expense | -20.45 | 16.5 | 22.2 | 41.6 | ||||||||||||
income-statement-row.row.net-income | 179.28 | 338.7 | 142.5 | 156 |
Често задавани въпроси
Какво е Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) общи активи?
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) общите активи са 4419458473.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 682215321.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -1.716.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -1.716.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.155.
Какъв е общият приход на предприятието?
Общият приход е 0.163.
Каква е Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е 338745242.000.
Какъв е общият дълг на фирмата?
Общият дълг е 1202607281.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 341371140.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 718411507.000.